Health minister promised improving pharma IP protection in Russia
This article was originally published in Scrip
Russia’s ministry of healthcare and social development has demonstrated that it is taking its new responsibility for the protection of pharmaceutical intellectual property seriously by signing a collaboration agreement with the federal service for intellectual property, patents and trademarks. The main objective of the collaboration is to raise the efficiency of IP protection in the pharmaceutical sector. But an industry reaction that has been muted to the point of disinterest indicates that there is a long way to go before the ministry’s move has significant impact. The agreement comes into force with the immediate effect.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.